Celgene's Revlimid misses in Phase III for follicular lymphoma

Celgene Corp. (NASDAQ:CELG) said Revlimid lenalidomide plus Rituxan rituximab missed the co-primary endpoints of improving complete response/unconfirmed complete response rate at 120 weeks and progression-free survival (PFS) in the Phase III RELEVANCE trial to treat previously untreated follicular lymphoma. Details were not disclosed.

The open-label trial evaluated Revlimid plus Rituxan followed by maintenance therapy with Revlimid plus Rituxan vs. standard of care (SOC) consisting of Rituxan plus chemotherapy (investigator’s choice of R-CHOP, R-bendamustine or R-CVP) followed by maintenance therapy with Rituxan...